CSIMarket
 
Seelos Therapeutics inc   (SEEL)
Other Ticker:  
 
 
Price: $0.9178 $-0.08 -7.990%
Day's High: $1.01 Week Perf: -18.78 %
Day's Low: $ 0.91 30 Day Perf: 10.43 %
Volume (M): 330 52 Wk High: $ 2.99
Volume (M$): $ 303 52 Wk Avg: $0.93
Open: $0.99 52 Wk Low: $0.10



 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 5
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -38
 Cash Flow (TTM) (Millions $) -13
 Capital Exp. (TTM) (Millions $) 0

Seelos Therapeutics Inc
Seelos Therapeutics Inc. is a biopharmaceutical company focused on developing novel treatments for central nervous system disorders. The company utilizes innovative technologies and scientific expertise to identify and develop potential therapies for diseases such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other neuropsychiatric disorders.

Seelos Therapeutics aims to address unmet medical needs by advancing promising drug candidates through clinical trials and regulatory approval processes. Their pipeline includes both early-stage and late-stage compounds that target different aspects of these disorders, ranging from neuroprotection to symptom management.

The company is committed to translating scientific discoveries into viable treatment options for patients. They collaborate with researchers, clinicians, and patient advocacy groups to ensure their therapies are developed with the patient's needs in mind.

Overall, Seelos Therapeutics Inc. strives to make a meaningful impact on the lives of individuals suffering from neurodegenerative and neuropsychiatric disorders by bringing innovative and effective therapies to market.


   Company Address: 300 Park Avenue New York 10022 NY
   Company Phone Number: 293-2100   Stock Exchange / Ticker: NASDAQ SEEL
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Seelos Therapeutics Inc

Seelos Therapeutics Inc Achieves Outstanding Revenue Growth in Fourth Quarter of 20232.

Seelos Therapeutics Inc, a major pharmaceutical preparations company, has recently announced strong revenue improvement in their fourth-quarter earnings for 2023. The company experienced a remarkable growth of 1562.5% year-on-year, with revenues reaching $0.67 million. However, despite this positive growth, the company also reported an increased loss per share of $-1.11, compared to a loss of $-0.12 per share in the previous reporting period. Additionally, revenue surged by 50.452% from $0.44 million.
In the fiscal period ending on December 31, 2023, Seelos Therapeutics Inc reported a net loss of $-5.453 million. This was a significant improvement compared to the deficit of $-18.657 million during the same period in the previous year. The company has been able to narrow its losses and improve its financial standing.

Seelos Therapeutics Inc

Major Pharmaceutical Company's Epic Surge in Revenue Fails to Turn Profitable: A Closer Look at Seelos Therapeutics' Financial Results



Seelos Therapeutics Inc, a leading pharmaceutical company in the Major Pharmaceutical Preparations sector, has reported impressive financial results for the period ending September 30, 2023. Despite the challenges faced by the industry, Seelos has shown significant growth in revenue. This article will further explore the company's financial results, analyze the impact of these results on Seelos Therapeutics, and provide insights into the company's future prospects.
Record Revenue Growth
Seelos Therapeutics Inc has witnessed a remarkable year-on-year revenue elevation of 1127.778%, reaching $0.44 million during the September 2023 financial period. This robust growth signifies the company's ability to perform even in a tough market. While many companies in the same industry are grappling with declining businesses and retracting revenue, Seelos is flourishing.

Seelos Therapeutics Inc

Seelos Therapeutics Inc: Revenue Soars to New Heights in Q2 2023, but Share Deficit Raises Concerns



Seelos Therapeutics Inc, a pharmaceutical company focused on developing novel therapeutics for central nervous system disorders, recently announced its financial results for the second quarter of 2023. The company reported a substantial increase in revenue, but the deficit per share also escalated. This article aims to analyze these financial results and provide the necessary context for a comprehensive understanding of Seelos Therapeutics Inc's performance.
Financial Analysis:
1. Revenue Growth: Seelos Therapeutics Inc witnessed a remarkable revenue growth of 2105.263% year on year, amounting to $0.42 million in the second quarter of 2023. This surge in revenue reflects the company's ability to generate significant sales during the reporting period.

Seelos Therapeutics Inc

Seelos Therapeutics Inc Surpasses Expectations with 3265% Revenue Increase in First Quarter of 2023 Earnings Season

Seelos Therapeutics Inc, a biopharmaceutical company that primarily focuses on the development of treatments for central nervous system disorders, recently announced a very solid revenue elevation of 3265.385% year on year to $0.88 million in its first quarter of 2023 earnings season. Despite this remarkable milestone, the company also reported an increased loss per share at $-0.12 from the previous financial reporting period of $0.00 per share. However, revenue doubled by 2087.5% from $0.04 million.
The financial period ending March 31, 2023, indicated that Seelos Therapeutics Inc reported a net loss of $-13.431 million, which is an improvement from a deficit of $-14.001 million in the same financial reporting period a year ago. The company's management, core research team, and stakeholders perceive this as a positive indication that their research is gaining momentum in treating central nervous system disorders.






 

Seelos Therapeutics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Seelos Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Seelos Therapeutics inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com